Foreword

Where Science Becomes Medicine

From Scientific Possibility to Patient Reality

Pharmaceutical progress is no longer measured simply by how quickly a promising molecule can move...

Strategy

From Volume to Value

The Structural Shift Reshaping Pharma

The pharmaceutical industry is in the middle of a genuine structural transition with a fundamental rethinking of where value...

Beyond Sterile

The Quiet Complexity of Non-Sterile Outsourcing

Discussions about pressure points in pharmaceutical manufacturing tend to move quickly to sterile injectables...

The Missing Middle of Pharma Personalisation

Pharma has spent years trying to personalise content. The bigger opportunity may be learning before personalising...

Research & Development

Next-Gen Immunotherapies

CAR-T, TILs, and Beyond

Immunotherapy has transformed the treatment of cancer and other serious diseases. The first wave of approved cell therapies...

Clinical Trials

How New Oligonucleotide Modalities Are Reshaping Preclinical Development

Oligonucleotide therapeutics are evolving beyond the early generation of antisense oligonucleotides (ASOs)...

Manufacturing

From Capability to Readiness

Why Biopharma Manufacturing Systems Still Fail Under Scrutiny

Biopharmaceutical manufacturing has never been as capable as it is today. Facilities are highly automated...

Emerging Frontiers in Cellular Immunotherapy

Navigating Innovation, Safety, and Ethical Considerations in Next-Generation Therapies

Immunotherapy has reshaped cancer treatment by leveraging immune mechanisms to recognize and destroy malignant cells...

Information Technology

Breaking Through Trial Complexity

How Agentic AI Is Reshaping Clinical Trials

Drug development is one of the most data-intensive endeavours in modern science, yet the industry continues to lose most...

Expert Talk

Building the Connected Patient Journey

How Recruitment, Decentralization, and Real-Time Data Are Converging in U.S. Clinical Trials

The first change is accountability. Recruitment cannot promise access that the protocol later makes difficult to deliver...

In Vivo Gene Therapy

Delivery vs Manufacturing Reality

In vivo gene therapy is technically advanced, yet commercially immature. While the science has advanced enough...

Agentic AI in Clinical Research

Traditional analytics describe what has happened or predict what might occur. Agentic systems go further: they reason towards a goal...

The Future of Multi-Modality CDMOs

Integrating Small Molecules, Peptides, and Advanced Therapies

What is changing is not simply the number of modalities but the way pipelines are built. A sponsor may have small molecules...

Cancer Drug Discovery

Fascinating Anecdotes of Oncology Medicine

In the last decade, oncology has garnered the most drugs approved by the FDA among all therapeutic areas...

Advertorials

Manufacturing as Strategy

Building Commercial Certainty in a Biologics-Driven Era

Biologics have permanently altered the risk profile of pharmaceutical commercialization. Advanced monoclonal antibodies...

Accelerating AI-Driven Drug Discovery

Integrating Cell-Free Expression with Purification-Free SPR

The advent of artificial intelligence (AI) is fundamentally restructuring the landscape of protein drug discovery...

BioPharma

Managing Biopharma R&D Pipelines in an Era of Scientific Innovation

Development Strategy Has Become a Defining Factor in Pipeline Performance

Pipeline discussions often focus on which molecules to advance. Far less attention is paid to how those molecules are developed...

Regulatory Consistency Enables Global Patient Access

The first biosimilar was approved in Europe in 2006, followed by the first biosimilar approval in the United States in 2015...

How Misaligned Pharma and Diagnostic Timelines Are Slowing Targeted Therapy Access

Targeted therapies depend on companion diagnostics (CDx) to identify the right patients. When those diagnostics...

Impact of Bispecific and Trispecific Antibodies on the Treatment of Blood Cancers

Bispecific antibodies have transformed the treatment of relapsed or refractory B-cell lymphomas and multiple myeloma...